In vivo inhibition of IFN-γ (and possibly IL-17)-producing NKT cells, for example, is a favorable pre-requisite for successful remission in patients with MS (57–59), and the effect of tetracyclines towards achieving this goal may provide an additional therapeutic tool, most likely in combination with standard treatment regimen in stratified cohorts of patients. Here, IL17A is linked to myeloid sarcoma.